CADTH Canadian Drug Expert Committee recommendation : Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity

MLA

CADTH Canadian Drug Expert Committee. CADTH Canadian Drug Expert Committee recommendation : Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity. First edition. Ottawa, ON : CADTH, 2018.

APA

CADTH Canadian Drug Expert Committee. (2018). CADTH Canadian Drug Expert Committee recommendation : Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity. First edition. Ottawa, ON : CADTH.

Chicago

CADTH Canadian Drug Expert Committee. CADTH Canadian Drug Expert Committee recommendation : Ocrelizumab (Ocrevus-Hoffmann-La Roche Limited) : indication : management of adult patients with early primary progressive multiple sclerosis (PPMS) as defined by disease duration and level of disability, in conjunction with imaging features characteristic of inflammatory activity. First edition. Ottawa, ON : CADTH, 2018.